Clinical Trial Results: An Open Label Study of ANX005 in Participants With, or at Risk for, Manifest Huntington's Disease [Phase 2]

View source ↗

Summary

Phase 2 open-label trial results for ANX005 in participants with or at risk for Huntington's disease have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Huntington Disease

Drugs mentioned

• ANX005

Snippet

Sponsor: Annexon, Inc. | Conditions: Huntington Disease | Phase 2 | Status: COMPLETED | Results posted: 2026-08-25